AveXis Night at BTEC set for Thursday, Nov. 15
Thursday, Nov. 15
BTEC room 135
The NC State chapter of ISPE is sponsoring AveXis Night at BTEC from 6:00–8:00 p.m. Thursday, Nov. 15, 2018. The evening will feature a presentation and question-and-answer session with senior leadership from AveXis at 6:00 p.m., followed by dinner and networking with AveXis employees.
AveXis currently is seeking full-time manufacturing associates and bioprocess engineers and has summer internships available. Dress is business casual, and the event takes place in room 135 at BTEC.
AveXis, Inc., a Novartis Company, is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and for the treatment of SMA Type 2. The U.S. Food and Drug Administration has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1 and Type 2, the firm also plans to develop other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene.